Epidemiology and Diagnosis of Patients With Squamous NSCLC
Optimal Management of Patients With Squamous NSCLC
- Individualizing choice of frontline therapy
- Advances in the management of patients after disease progression
- Management of treatment-related adverse events
Future Directions for the Treatment of Squamous NSCLC
Question and Answer Session
Date / Time
Washington Cancer Institute
Edward Kim, MD
Chair, Solid Tumor Oncology and Investigational Therapeutics
Solid Tumor Oncology
Levine Cancer Institute/Carolinas Healthcare System
Charlotte, North Carolina
Mark Anthony Socinski, MD
Executive Medical Director
Member, Thoracic Oncology Program
Florida Hospital Cancer Institute
Young Kwang Chae, MD, MPH, MBA
Co-Director, Developmental Therapeutics Program Division of Hematology/Oncology
Department of Medicine
Northwestern University Feinberg School of Medicine
Robert H. Lurie Comprehensive Cancer Center
Thomas Hensing, MD
Clinical Associate Professor of Medicine
The University of Chicago Illinois
Nathan Pennell, MD, PhD
Director, Cleveland Clinic Lung Cancer Medical Oncology
Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Thomas Stinchcombe, MD
Thoracic Oncology Program
University of North Carolina Lineberger
Comprehensive Cancer Center
Chapel Hill, North Carolina
Anne S. Tsao, MD
Director, Mesothelioma Program
Director, Thoracic Chemo-Radiation Program
Department of Thoracic/Head and Neck Medical Oncology
Division of Cancer Medicine
The University of Texas M. D. Anderson Cancer Center
The goal of this activity is to improve participants’ competence in providing optimal care for patients with squamous non-small-cell lung cancer.
This program is intended for physicians, registered nurses, pharmacists, and other healthcare professionals who care for patients with non-small-cell lung cancer.
- Plan individualized treatment strategies for patients with newly diagnosed squamous NSCLC
- Incorporate current evidence-based treatment recommendations into the care of patients with metastatic squamous NSCLC that has progressed on or after frontline therapy
- Discuss promising investigational agents and emerging therapeutic strategies with patients with squamous NSCLC based on an understanding of available clinical data and ongoing clinical trials
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
1.0 contact hour may be earned for successful completion of this activity.
California Board of Registered Nursing
Provider approved by the California Board of Registered Nursing, Provider Number 13664, for 1.0 contact hour.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 4 weeks
Pharmacist Continuing Education
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This program has been assigned ACPE Universal Activity #0797-9999-17-066-L01-P. This program is designated for up to 1.0 contact hour (0.10 CEUs) of continuing pharmacy education credit.
Type of Activity: Application
For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Disclosure of Conflicts of Interest
The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.